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WWOX sensitises ovarian cancer cells to paclitaxel via
modulation of the ER stress response
Szymon Janczar1,2,5, Jaya Nautiyal1,5, Yi Xiao1, Edward Curry1, Mingjun Sun1, Elisa Zanini1, Adam JW Paige1,3,5 and Hani Gabra*,1,4,5
There are clear gaps in our understanding of genes and pathways through which cancer cells facilitate survival strategies as they
become chemoresistant. Paclitaxel is used in the treatment of many cancers, but development of drug resistance is common.
Along with being an antimitotic agent paclitaxel also activates endoplasmic reticulum (ER) stress. Here, we examine the role of
WWOX (WW domain containing oxidoreductase), a gene frequently lost in several cancers, in mediating paclitaxel response. We
examine the ER stress-mediated apoptotic response to paclitaxel in WWOX-transfected epithelial ovarian cancer (EOC) cells and
following siRNA knockdown of WWOX. We show that WWOX-induced apoptosis following exposure of EOC cells to paclitaxel is
related to ER stress and independent of the antimitotic action of taxanes. The apoptotic response to ER stress induced by WWOX
re-expression could be reversed by WWOX siRNA in EOC cells. We report that paclitaxel treatment activates both the IRE-1 and
PERK kinases and that the increase in paclitaxel-mediated cell death through WWOX is dependent on active ER stress pathway.
Log-rank analysis of overall survival (OS) and progression-free survival (PFS) in two prominent EOC microarray data sets (Tothill
and The Cancer Genome Atlas), encompassing ~ 800 patients in total, confirmed clinical relevance to our findings. High WWOX
mRNA expression predicted longer OS and PFS in patients treated with paclitaxel, but not in patients who were treated with only
cisplatin. The association of WWOX and survival was dependent on the expression level of glucose-related protein 78 (GRP78), a
key ER stress marker in paclitaxel-treated patients. We conclude that WWOX sensitises EOC to paclitaxel via ER stress-induced
apoptosis, and predicts clinical outcome in patients. Thus, ER stress response mechanisms could be targeted to overcome
chemoresistance in cancer.
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Epithelial ovarian cancer is the most lethal gynaecological
malignancy. Use of platinum and taxane-based chemotherapy
result in high response rates, but 70% of patients relapse and
develop drug-resistant disease.1 Paclitaxel stabilises micro-
tubule assembly, resulting in a mitotic block of cell cycle
leading to apoptosis.2 The cytotoxic effects of taxanes are not
just because of its antimitotic function3 but are, in part,
mediated by endoplasmic reticulum (ER) stress/unfolded
protein response (UPR).4–8 UPR is a programme initiated by
the accumulation of unfolded proteins in ER to re-establish
homeostasis by activation of chaperones and translation
inhibition.9
The WWOX (WW domain containing oxidoreductase) gene
on chromosome 16q23-24 is located at the same locus as the
common fragile site FRA16D.10 WWOX loss increases tumour
susceptibility in several mouse models.11–13 WWOX expres-
sion is lost or downregulated in most cancers because of
genomic disruption or epigenetic silencing, and recently The
Cancer Genome Atlas data sets have highlighted 44 novel
somatic mutations in WWOX in various cancer types, several
of which lead to changes in the protein function.14–18 WWOX
is highly expressed in secretory epithelia, in reproductive,
exocrine and endocrine organs and also in neuronal bodies
throughout the central nervous system. Mutations in WWOX
have been reported in several neurological pathologies.18,19
WWOX is lost in 30% of ovarian carcinomas and this is
associated with disease progression, and poor prognosis.20
We previously demonstrated that WWOX transfection of
PEO1 ovarian cancer cells abolished their in vivo tumorigeni-
city because of altered interaction of tumour cells with
surrounding ECM.21 This did not correlate with decreased
in vitro growth or survival, but was as a result of reduced
integrin α3 levels.21 There was also no effect of WWOX on
apoptosis following cisplatin exposure.21 As standard che-
motherapy treatment in ovarian cancer is a combination of
platinum and paclitaxel, we examined the impact of WWOX
transfection on paclitaxel response. We report that WWOX
transfection into the non-expressing PEO1 ovarian cancer cell
line21,22 causes sensitisation to paclitaxel, as demonstrated by
increased apoptosis following exposure with paclitaxel. This is
independent of the antimitotic function of taxanes, but is
related to apoptosis because of ER stress induced by
paclitaxel. To mimic the natural course of events involving
WWOX loss in cancer, we used siRNA knockdown of
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endogenous WWOX to study its role in paclitaxel-induced cell
death in SKOV-3 and OVCAR-4 cell lines. We conclude that
(1) both IRE-1 and PERK arms of UPR get activated on
exposure of ovarian cancer cells to paclitaxel and active ER
stress is a requirement forWWOX-mediated cell death caused
by paclitaxel and (2) WWOX expression may predict patient
outcome to taxane-based chemotherapy.
Results
WWOX sensitises ovarian cancer cells to paclitaxel.
WWOX reconstitution in PEO1 ovarian cancer cells
(WWOX-7, WWOX-8) significantly enhanced paclitaxel-
mediated cell death (Figures 1a, Po0.01) compared with
vector-transfected control cells (Vector-9, Vector-p2). We
examined caspase activation, Annexin V positivity and an
antibody array to measure the relative levels of apoptosis-
related proteins in these cell lines. WWOX transfection
significantly increased caspase-3/7 activation following expo-
sure with paclitaxel 24 h at either 8 or 16 nM, as compared
with the vector-transfected control lines (Figures 1b,
Po0.05). Increased levels of cleaved caspase-3 was
observed in WWOX-transfected lines on treatment with
paclitaxel (Figure 1c). Following paclitaxel exposure,
WWOX-transfected cells also displayed significantly higher
levels of early apoptotic cells (Annexin V-positive,
PI-negative) (Figures 1d, Po0.05). The antibody array
demonstrated no consistent differences in the expression of
apoptosis-related proteins in basal conditions, but upon
paclitaxel exposure, a lower B-cell lymphoma-extra large
(Bcl-xL)/Bcl-2-associated x (Bax) ratio in WWOX-transfected
cells was observed (Figure 1e).
Two independent siRNA oligos were used to knockdown
WWOX in WWOX-8 cell line. This decreased the apoptotic
response to these cells to 8 and 16 nM paclitaxel (not shown)
as compared with control transfections (Figures 2a, *Po0.05
and ***Po0.005) and cleaved caspase-3 expression
(Figure 2b), confirming that paclitaxel chemoresponse is
influenced by WWOX expression. In parallel, WWOX status
has no impact on cisplatin response (Figure 2c) to comple-
ment the previous data generated with stable transfectants.21
To mimic the loss/reduction of WWOX as it happens in the
course of cancer, we knocked down endogenous WWOX in
ovarian cancer cells to monitor the impact on cell survival. We
screened several ovarian cancer cells to detect WWOX
expression (Figure 2d) and found endogenous protein
expression in OVCAR-4, OVCAR-8, SKOV-3 and A2780 cell
lines (Figure 2d). siRNA knockdown of WWOX in OVCAR-4
and SKOV-3 cell lines led to (Figure 5b) an improvement in cell
survival in both SKOV-3 (Figure 2e, P= 0.0082) and OVCAR-4
cell lines (Figure 2f, P= 0.0022) on treatment with 50 and
20 nM paclitaxel, respectively.
WWOX-driven differential response to paclitaxel is
independent of the antimitotic action of taxanes, integrin
α3 and transforming growth factor-β1 levels. We next
examined mitotic arrest in paclitaxel-treated cells to deter-
mine whether reduced survival following WWOX overexpres-
sion was due to an increased proportion of cells arrested in
mitosis (Figure 3a). WWOX status had no impact on the
response of PEO1 cells to the kinesin Eg5 inhibitor
monastrol, a selective antimitotic agent23 (Figure 3b). Thus,
the effect of WWOX on paclitaxel response is distinct from the
antimitotic function of taxanes. We hypothesised that a
differential response to paclitaxel treatment following WWOX
transfection might be due to ITGA3 regulation.21 However, we
observed no significant impact of ITGA3 knockdown in PEO1
cell line on responses to paclitaxel (Figures 3c and d). We
examined the the levels of transforming growth factor-β1
(TGFB1), which has previously been shown to be a critical
mediator of paclitaxel response in ovarian cancer.24 We could
not detect measurable levels of secreted TFGB1 in culture
medium in PEO1 clones, but quantitative RT-PCR (QPCR)
revealed variable TGFBI levels and no correlation with
WWOX expression (Figure 3e).
Paclitaxel induces ER stress response and WWOX
determines cell fate in response to prolonged ER
stress. Treatment of PEO1 cells with 8 nM paclitaxel led to
induction of ER stress, as indicated by upregulation of
GRP78 chaperone and phosphorylation of eukaryotic trans-
lation initiation factor 2A (eIF2A), as well as c-Jun N-terminal
kinase (JNK) and p38 mitogen-associated protein kinase
(MAPK) activation25 (Figure 4a and Supplementary Figure 1).
Similar changes were observed in a parallel time-course
experiment following exposure to tunicamycin, a classic
inducer of ER stress25 (Figure 4b). WWOX-transfected cells
displayed significantly reduced survival rates when exposed
to tunicamycin (200 ng/μl) (Figure 4c, Po0.005), whereas
WWOX siRNA knockdown increased survival (Figures 4d,
Po0.01 and Figure 4e, Po0.05). Thus, WWOX expression
directs UPR induced by tunicamycin or paclitaxel towards an
apoptotic outcome. WWOX-dependent apoptosis during ER
stress was examined in context of MAPK signalling.26
Inhibition of JNK27 abrogated paclitaxel response in
WWOX-8 cells (Supplementary Figure 2) but marginally
prevented tunicamycin toxicity (Supplementary Figure 3).
Inhibition of JNK quite remarkably antagonised the antimitotic
(Supplementary Figure 4) function of taxanes in PEO1 cells.
We found no evidence of WWOX-JNK1 interaction in
co-immunoprecipitation experiments following exposure with
paclitaxel (Supplementary Figure 5 and not shown).
To investigate ER stress induced by paclitaxel and the role
of WWOX in this context, we carried out analysis of (1)
PEO1 cells (Figures 5a) and (2) by knocking down endogen-
ous WWOX expression in SKOV-3 and OVCAR-4 cell lines
(Figure 5b). We examined the expression of the two key ER
transmembrane kinases IRE-1 and PERK, which activate ER
stress responses. Both IRE-1 and PERK showed induction or
increase of phosphorylation under the influence of paclitaxel in
all cell lines compared with untreated cells. When probed with
a phosphorylated IRE-1 antibody, a band at 110 kDa
appeared in paclitaxel-treated cells. The identity of this band
was confirmed using another antibody detecting total IRE-1
protein (Figures 5a and b). In a control treatment of the cells
with thapsigargin (a strong inducer of ER stress), a slightly
upward shifted pIRE-1 band was observed (Supplementary
Figure 6), suggesting differences in the phosphorylation status
of the protein under paclitaxel and thapsigargin treatments. It
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Figure 1 WWOX-transfected PEO1 lines show increased apoptosis following treatment with paclitaxel, compared with vector-transfected lines. (a) Relative cell survival
following treatment with paclitaxel for 72 h, measured by SRB assay. Means of quadruplicate experiments± S.E.M. (b) Caspase-3/7 activation following treatment with paclitaxel
for 24 h, measured by CaspaseGlo3/7 reagent (Promega). Means of six experiments± S.E.M. (c) Immunoblot showing activated caspase-3 levels (MAB835 antibody; R&D
Systems) following treatment with 8 nM of paclitaxel for 24 h. β-Actin bands (AC15 antibody; Sigma) show equal loading of blot and WWOX immunoblot (antibody gifted by Dr. M
Aldaz, MD Anderson Cancer Centre) demonstrates successful knockdown. (d) Early apoptotic (Annexin V-positive/propidium iodide (PI)-negative) cells following treatment with
paclitaxel for 24 h. Means of quadruplicate experiments±S.E.M. (e) Left panel: Bcl-xL and Bax probe spots from protein arrays, showing increased Bax and decreased Bcl-xL in
WWOX-transfected lines following exposure with paclitaxel for 24 h; right panel: densitometry from protein array shows lower Bcl-xL:Bax ratio in WWOX-transfected cells treated
with paclitaxel. Means of two probe spots± S.D. (*Po0.05; **Po0.01)
WWOX increases paclitaxel response
S Janczar et al
3
Cell Death and Disease
was noteworthy, however, that the intensity of the pIRE-1 band
induced by thapsigargin was less in WWOX-null Vector-9
compared withWWOX-overexpressingWWOX-8 cells indicat-
ing higher levels of ER stress in the latter (Supplementary
Figure 6). PERK expression showed a shift from a distinct
lower band in untreated conditions to a characteristic fuzzy
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upward shifted band/smear after paclitaxel treatment (Figures
5a and b), indicating activation of PERK.28,29 A similar
response was observed on treating the PEO1 cells with
thapsigargin and analysing PERK expression with a different
antibody (abcam, Cambridge, UK; ab65142). No changes in
activation of PERKwere observed as a result of WWOX status
(Figures 5a and b and Supplementary Figure 6). Changes in
the phosphorylated status of JNK1/2 in the PEO1 cells with
WWOX overexpression were observed, but this was not pro-
nounced in SKOV-3 and OVCAR-4 cells with WWOX knock-
Figure 2 Knockdown of WWOX in WWOX-transfected PEO1, SKOV-3 and OVCAR-4 cells decreases apoptosis following treatment with paclitaxel compared with
non-targeting controls. (a) Relative cell survival following treatment with paclitaxel for 72 h, measured by SRB assay. Means of quadruplicate experiments± S.E.M. Western blot
shows loss of WWOX expression after treatment with WWOX siRNA for 72 h, as compared with mock-transfected and non-targeting cells in PEO1 cells. (b) Immunoblot showing
activated caspase-3 levels (MAB835 antibody; R&D Systems) following treatment with 8 nM of paclitaxel for 24 h. Hsp60 (ab46798 antibody; abcam) bands show equal loading of
blot, while WWOX blot shows successful knockdown in PEO1 cells. (c) Relative cell survival following treatment with cisplatin for 72 h, measured by SRB assay. Means of
triplicate experiments± S.E.M. (*Po0.05; ***Po0.005). (d) Immunoblot showing endogenous WWOX expression (ab137726 antibody; abcam) in ovarian cancer cell lines.
β-Actin (no. 4970; Cell Signalling Technology) has been used as a loading control. Relative cell survival 72 h after treatment with siWWOX or non-targetting control and 48 h after
treatment with 50 and 20 nM paclitaxel in SKOV-3 (e) and OVCAR-4 (f) cells, respectively
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Figure 3 The differential response of WWOX-transfected cells to paclitaxel is not related to the antimitotic action of taxanes, and WWOX-induced apoptosis is independent of
ITGA3 and TGFBI. (a) WWOX transfection does not alter the percentage of mitotic (MPM2 antibody-labelled (Millipore)) cells as determined by FACS following treatment with
paclitaxel. Means of triplicate experiments± S.E.M. (b) WWOX depletion does not alter the cytotoxic response to monastrol. Cell survival following treatment with monastrol for
72 h, measured by SRB assay. Means of triplicate experiments± S.E.M. (c) ITGA3 expression following siRNA knockdown as measured by FACS, compared with
mock-transfected and non-targeting siRNA. Means of quadruplicate experiments± S.E.M. (d) ITGA3 siRNA knockdown did not affect cell survival following exposure with 8 nM
paclitaxel, measured by SRB assay. Means of six experiments±S.E.M. (e) TGFBI mRNA expression is not related to WWOX expression in WWOX- and vector-transfected PEO1
lines. Means of six experiments±S.E.M. NT, non-targeting siRNA
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down. To examine upstream events in the ER stress-mediated
apoptosis analysis of expression of procaspase and cleaved
caspase-2 and -7 was performed. Increase in the expression
of cleaved caspase-7 in paclitaxel-treated cells (Supplem-
entary Figure 7) was observed, but this was not influenced by
WWOX expression. Subtle increase in the expression of
cleaved caspase-2 in paclitaxel-treated WWOX-overexpres-
sing PEO cells and a reduction in SKOV-3 and OVCAR-4 cells
on siWWOX was observed (Supplementary Figure 7).
Since the adaptive and maladaptive arms of UPR coexist
under ER stress, it is essential to determine which arm is
dominant in paclitaxel-induced ER stress and how these are
affected by WWOX expression. Thus, cells were treated with
paclitaxel alone or in combination with IRE-1 inhibitor KIRA6
and/or PERK inhibitor GSK2656157 and cell viability was
analysed. As observed in the earlier results (Figures 1a and
2e, f), WWOX expression sensitised all three cell lines, that is,
PEO1 (Figure 5c), SKOV-3 (Figure 5d) and OVCAR-4 cells
(Figure 5e) to paclitaxel-induced cell death. Cotreatment of
cells with KIRA6 and paclitaxel improved cell viability
compared with the paclitaxel-alone group in all cell lines
(Figures 5c–e). Combination of PERK inhibitor, GSK2656157,
with paclitaxel enhanced cell survival in only SKOV-3 cells
(Figure 5d). Notably, in the absence of WWOX in PEO1 cells
(Vector-9) or when WWOX expression was knocked down by
siRNA in SKOV-3 and OVCAR-4, cells were less sensitive to
KIRA6 and GSK2656157 as shown by the blunted effects on
cell viability (Figures 5c–e) compared with the respective
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Figure 4 Paclitaxel evokes ER stress in PEO1 cells and WWOX sensitises PEO1 cells to the ER stress inducer tunicamycin. (a) WWOX-8 and control Vector-9 cells were
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paclitaxel-alone treated groups. Among the combination
treatments, the visible rescue in cell viability on WWOX
knockdown was seen in GSK2656157-treated OVCAR-4
cells, indicating that WWOX may not be acting by regulating
cell survival through the PERK pathway in this cell line
(Figure 5e). To further examine the impact of the IRE-1 and
PERK inhibitors with paclitaxel on cell survival, we carried out
propidium podide (PI) staining in OVCAR-4 and SKOV-3 cells
treated with paclitaxel alone or in combination with KIRA6 and
GSK2656157. Combination of IRE-1 inhibitor KIRA6 with
paclitaxel reduced cell death, while combination with the
PERK inhibitor GSK2656157 led to no change or slight
increase in cell death (Supplementary Figure 8), indicating
that the two pathways might have different roles in mediating
the response to paclitaxel in these ovarian cancer cell lines
(Figure 5 and Supplementary Figure 8).
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Vector-9
Figure 5 WWOX regulates ER stress through IRE-1 and PERK. Western blots showing the expression of WWOX and ER stress regulators IRE-1 (ab48187 and ab37073
antibodies; abcam), PERK (no. 3192; Cell Signalling Technology), JNK (MAB2076 (Total) and AF1205 (phospho) antibodies; R&D Systems) (a) untreated or treated with 8 nM
paclitaxel for 24 h in PEO1 cell lines in the presence or absence of WWOX. (b) SKOV-3 and OVCAR-4 cells, 72 h after treatment with siWWOX or no targeting control and 24 h
after treatment with paclitaxel in 50 nM SKOV-3 and 20 nM OVCAR-4 cells. β-Actin has been used as a loading control. Cell viability was measured through SRB assay in (c)
WWOX-8 and Vector-9 (d) SKOV-3 (72 h siRNA treatment) and (e) OVCAR-4 cells (72 h siRNA treatment) with IRE-1 inhibitor (KIRA6; 532281; Calbiochem) and PERK
(GSK2656157; S7033; Selleckchem) alone or together in combination with paclitaxel. Cells were treated with 1 μg/μl inhibitors 2 h before paclitaxel treatment for 24 h. Triplicate
experiments were performed
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WWOX expression predicts PFS in paclitaxel-treated
ovarian cancer patients. We used data from two large
cohorts of primary ovarian tumours to investigate the
associations between WWOX expression and clinical
outcome to chemotherapy. The data set referred to as
‘TCGA’, featuring over 500 primary tumour samples, was
obtained from The Cancer Genome Atlas (https://tcga-data.
nci.nih.gov/tcga/)30 The data set referred to as ‘Tothill’,
featuring nearly 300 primary tumour samples, was obtained
from Gene Expression Omnibus (series accession
GSE9891).31 Raw gene expression data (Affymetrix CEL
files) were obtained for each data set and normalised using
robust multiarray average (RMA).32
WWOX expression and OS: Fitting Cox proportional hazards
regression models revealed significant association between
higher WWOX expression and longer OS in patients treated
with platinum in combination with taxane in both TCGA
(n=373, hazard ratio= 0.48, P=0.036) and Tothill (n= 194,
hazard ratio= 0.53, P=0.028) cohorts. In both the cohorts
higher expression of WWOX was associated with longer
survival times even when the extent of disease after primary
surgery was taken into account (TCGA hazard ratio= 0.48,
P=0.046; Tothill hazard ratio= 0.67, P= 0.19), implying that
WWOX levels had a clear impact on patient survival. When
the patients who received taxanes in the first-line chemother-
apy are excluded, the association between WWOX expres-
sion and OS was lost (TCGA n= 33, hazard ratio=1.9,
P=0.64; Tothill n=48, hazard ratio= 1.0, P=0.98). To
illustrate these associations, Figures 6a and c show
Kaplan–Meier plots of OS when patients are partitioned into
WWOX-high (greater than median expression) and WWOX-
low subsets, for the cohorts receiving both platinum and
taxane. P-values reported in the figures represent results
from log-rank test based on dichotomisation used to draw
curves. Figures 6b and d show equivalent Kaplan–Meier
plots of OS in patients who received platinum alone. Thus,
across independent data sets taxane-specific association
between higher WWOX expression and longer patient OS
was observed. As WWOX is often deleted in tumours, we
investigated the TCGA data set to understand the impact on
survival of WWOX expression being classed as detectable or
absent relative to normal physiological levels. Using the
median expression across normal tissue samples (eight
normal samples in TCGA) to estimate population mean, and
the median absolute deviation to estimate the population
standard deviation, the 10th percentile of expression (extra-
polated from a normal distribution across the normal tissues)
was used as a cutoff to reflect present versus absent WWOX
expression in patient samples. Figures 6e and f show that
patients who received Taxol showed longer OS in the
presence of WWOX compared with the absence of WWOX
(n=373, P=0.050) and this distinction was lost in the
absence of Taxol (n=33, P= 0.92).
WWOX expression and PFS: We further investigated the
association between WWOX expression and progression-
free survival (PFS) (time of death or disease progression).
Figures 7a–d represent Kaplan–Meier curves of PFS for
patients partitioned into WWOX-high (greater than median
expression) or WWOX-low. In both TCGA and Tothill cohorts,
when patients were treated with platinum and taxane, those
with higher WWOX expression had significantly longer PFS
than those with lower WWOX (TCGA n= 333, P=0.011;
Tothill n= 191, P=0.00045). However, no significant differ-
ence in PFS according to WWOX expression was observed
in patients who received the platinum alone (Figures 7b
and d). We used the TCGA data set to investigate the impact
on progression of WWOX expression being classed as
detectable or absent relative to normal physiological levels.
Corresponding Kaplan–Meier curves in Figures 7e and f
show that, in patients treated with platinum and taxane
(Figure 7e) but not in patients treated with platinum alone
(Figure 7f), this dichotomisation suggests longer PFS in
patients with WWOX expression detectable at a level
comparable to normal tissue.
WWOX expression influences ovarian cancer molecular
subtypes: WWOX expression showed very significant varia-
tion in expression levels across the molecular subtypes
reported in the Tothill study.31 The poor outcome ovarian
cancer subtype ‘1’ had lower WWOX expression across three
probesets (Figure 8a, P=0.0035; left, Po1x10− 4; middle
and P=0.00069; right), implying that the loss of WWOX
expression has a role in development of aggressive
characteristics of this subtype of ovarian cancer.
WWOX, associations with ER stress genes and influence on
survival: To investigate the clinical relevance of WWOX
expression and ER stress genes on survival, we investigated
the interaction between a panel of genes transcriptionally
upregulated by ER stress (GRP78, XBP1, ATF6, eukaryotic
translation initiation factor 2-alpha kinase 3 (EIF2AK3), ERN1
and DNA damage-inducible transcript 3) and association of
WWOX expression. For each of the panel of genes,
proportional hazards regression models were fitted to
evaluate the additive effects of WWOX and the ER stress
gene, and the interaction between the two genes. It was
striking that the association between higher WWOX expres-
sion and better outcomes (longer OS and PFS) was
dependent on the endogenous levels of GRP78
(Figures 8b–e) but none of the other factors examined (not
shown). GRP78 is the best described marker of ER stress,
regarded as a key regulator of multiple arms of the UPR, and
transcriptionally regulated via conserved ER stress response
elements in its promoter.9 We found that the impact of WWOX
expression on OS (Figures 8b and c) and PFS (Figures 8d
and e) was effectively seen in patients (Tothill data set) who
had lower endogenous expression of GRP78 (Figures 8c
and e) and not in those who had higher GRP78 expression
(Figures 8b and d). The patients were split according to
GRP78 expression being above or below the median value.
The median was 2.42-fold greater than the minimum value
and 3.25-fold lower than the maximum value, making the total
range of expression (lowest to highest) 7.89-fold. The
samples with high GRP78 expression likely represent
tumours with intrinsic ER stress leading to apoptosis,
irrespective of chemotherapy, and it might be speculated that
WWOX status has no impact on these tumours, which have
activation of proapoptotic pathways before chemotherapy
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Figure 6 WWOX levels predict OS in taxane-treated ovarian cancer patients. Kaplan–Meier plots to show the effect of WWOX expression on OS in two ovarian cancer
cohorts, namely (a) TCGA (n= 491) and (b) Tothill (n= 258). OS plots of patients in the TCGA cohort treated with platinum alone (d) and taxane+platinum (c) and survival plots in
the Tothill data set of patients treated with platinum alone (f) or taxane+platinum (e). Red line represents patients with higher WWOX expression, whereas black line represents
patients with lower WWOX expression. (g and h) OS curves when the TCGA data set was analysed, setting a cutoff to reflect the absence or presence of WWOX in patients who
received platinum treatment (h) or platinum in combination to paclitaxel (g). Black represents WWOX absence, whereas red line represents WWOX expression
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Figure 7 WWOX levels predict PFS in taxane-treated ovarian cancer patients. Kaplan–Meier plots to show the effect of WWOX expression on PFS in two ovarian cancer
cohorts namely (a) TCGA (n= 491) and (b) Tothill (n= 258). PFS plots of patients in the TCGA cohort treated with platinum alone (d) and taxane+platinum (c) and survival plots
in the Tothill data set of patients treated with platinum alone (f) or taxane+platinum (e). Red line represents patients with higher WWOX expression, whereas black line represents
patients with lower WWOX expression
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Figure 8 Lower WWOX is characteristic of more aggressive type of ovarian cancer and improved survival through WWOX involves ER stress. (a) Box plots to show WWOX
expression across three probesets demonstrating in all three that the most aggressive tumour type namely ‘1’ has significantly lower WWOX expression.31 Kaplan–Meier plots to
show that the effect of WWOX expression on OS (b and c) and PFS (d and e) was effectively seen in patient cohorts that had lower endogenous expression of GRP78 (c and e)
and not in those with higher GRP78 expression (b and d)
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commences. Also, tumours with high GRP78 may represent
evolved tumours with intrinsic ER stress, which is more
inclined towards a cytoprotective UPR function. Conversely,
WWOX appears to strongly affect PFS in the ‘low GRP78’
tumours, and this may correspond to tumours with intrinsi-
cally low, but paclitaxel-inducible, ER stress. These data
suggest an inter-relationship between WWOX and the UPR.
We could not however detect any interaction between
WWOX and GRP78 under the influence of paclitaxel in
co-immunoprecipitation assays performed in WWOX-8 cells
(Supplementary Figure 9).
Discussion
The combination of platinum and taxanes is the gold standard
for chemotherapy in ovarian cancer; however, cure rates
remain low. Our data suggest that WWOX regulates taxane
response in ovarian cancer bymodulating the drug-related ER
stress response. One-third of ovarian cancers exhibit loss of
WWOX protein20 and these would therefore be expected to
respond less to paclitaxel. Turning to the clinical relevance of
our findings, WWOX expression levels predicted longer OS
and PFS in a population of paclitaxel-treated ovarian cancer
patients.
Recently, WWOX has been shown to be responsible for
cancer cells' response to chemotherapy on two accounts.
WWOX sensitises squamous cell carcinoma cells to apoptosis
induced by the antifolate chemotherapeutic agent methotrex-
ate by regulating autophagy responses in cancer cells and
absence of WWOX leads to chemotherapeutic drug
resistance.33 A second study demonstrated that WWOX
through its WW1 domain interacts with the p53 homologue
protein ΔNP63 known to induce chemoresistance in cancer
cells. WWOX sequesters ΔNP63 in the cytoplasm, thus
changing its cellular location and transactivation of its target
genes. WWOX could reverse ΔNP63-induced chemoresis-
tance to cisplatin by sensitising cancer cells to cisplatin-
induced cell death.34
ER stress response is also activated in hypoxic or nutrient-
deprived tumours,9,25,35–38 and thus WWOX loss might be the
key to multistep carcinogenesis that enables tumours reach-
ing a macroscopic size to survive under conditions of cellular
stress due to stimuli such as hypoxia. WWOX, via its WW
domain, physically interacts with hypoxia-inducible factor 1α
subunit and modulates its levels and transactivation
functions.39 Multiple myeloma cells are stressed by unfolded
protein overload because of their production of monoclonal
immunoglobulins. Interestingly, WWOX is frequently lost or
undergoes recurrent genomic alterations in multiple myeloma
and this is associated with poor outcomes.40–46 Tumours
resembling human multiple myeloma were also noted in
WWOX-deficient mice.12
Here, through modulating WWOX expression in ovarian
cancer cells we show that WWOX influences paclitaxel-
induced cell death through ER stress pathway and an intact
IRE-1 arm of UPR is crucial for WWOX to function. The
bioinformatics data presented in Figure 8 captured the
expression levels of GRP78 to be a determinant and an
indicator of WWOX-mediated influences on patient survival.
GRP78 activates all arms of ER stress including IRE-1 and
PERK and its expression along with WWOX could be used as
a predictive biomarker of patient responses to paclitaxel
treatment. WWOX interacts with SCOTIN/SHISA5,47 which
was recently demonstrated to be a proapoptotic protein
involved in ER stress response.48,49 With two interaction-rich
WW domains and an enzymatic tail, WWOX could be involved
in protein transport, act as a chaperone or it may regulate
redox status, particularly since WWOX knockout mice display
severe metabolic abnormalities.50,51 WWOX involvement in
ER stress response is consistent with the stress response
network hypothesis for common fragile site genes based on
the conservation of their loci including the intronic or intragenic
fragile site structure that could serve as stress sensors and
involvement in stress response already ascribed to WWOX,
fragile histidine triad and RAR-related orphan receptor.52 In
conclusion, our study provides novel insights into the function
of the WWOX and suggests that defective proapoptotic
signalling during ER stress response associated with loss of
WWOX may confer paclitaxel resistance in a proportion of
ovarian cancer patients. In general, adaptive UPR mechan-
isms could be targeted to increase chemotherapy efficacy
where that cytotoxic mechanism is mediated by ER stress.
Materials and Methods
Cell lines. The PEO1 ovarian cancer cell line (derived within our previous
laboratory in University of Edinburgh) is homozygously deleted for WWOX
exons 4–8 and lacks WWOX protein expression. We developed independent stable
WWOX- and vector-transfected lines as described previously.21,22 Cells were
maintained in RPMI containing 10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin
(and 3 μg/ml blasticidin for stably transfected cells) and cultured at 37 °C, 5% CO2.
PEO1 line derivatives were recently authenticated by confirming the presence of a
specific homozygous deletion within WWOX by RT-PCR; the presence of plasmid
vector by blasticidin selection; and that WWOX was expressed in WWOX-transfected
lines, but null in vector-transfected lines by qRT-PCR and immunoblotting.21,22
Growth curves. Log-phase cells (6 × 103 per well) were seeded into 96-well
plates. Following 24 h incubation, media were replaced with media containing
paclitaxel, cisplatin, monastrol, tunicamycin, SP600125, KIRA6 or GSK2656157.
Monastrol and SP600125 were obtained from Tocris Bioscience (Bristol, England,
UK) and tunicamycin from Sigma-Aldrich (St. Louis, MO, USA), KIRA6 from
Calbiochem (San Diego, CA, USA) and GSK2656157 from Selleckchem (Houston,
TX, USA). Cells were quantified by sulforhodamine B (SRB) assay.
Caspase-3/7 activation assays. Log-phase cells (1.5 × 104 per well) were
seeded into 96-well plates. Following 24 h incubation, media were replaced with
media containing paclitaxel. Caspase-3/7 activity was measured after 24 h of drug
exposure with CaspaseGlo3/7 Assay Kit (Promega, Fitchburg, WI, USA).
Annexin V apoptosis assays. Log-phase cells (2.5 × 105 per well) were
seeded into 6-well plates. Following 24 h incubation, media were replaced with
media containing paclitaxel. After 24 h of drug exposure, floating and adherent cells
were collected and Annexin V measured by flow cytometry using TACSTM Annexin
V-FITC Apoptosis Detection Kit (R&D Systems, Minneapolis, MN, USA).
Measuring mitotic index. Cells were plated and treated as for Annexin V
assays. Following drug exposure, the cells were fixed with 2% paraformaldehyde,
blocked with 1% BSA and permeabilized with 1 × BDPerm/Wash solution (BD
Biosciences, San Jose, CA, USA). Cells (2 × 105) were stained with 1:100 dilution of
anti-MPM2 antibody (Millipore, Leicester, UK), followed by incubation with 1:500
dilution of secondary fluorescein isothiocyanate (FITC)-conjugated antibody
(Sigma-Aldrich). Cells were analysed by fluorescence-activated cell sorting (FACS)
and the percentage of MPM2-positive cells was designated as mitotic index.
RNAi transfections. A total of 2.5 × 105 cells were incubated in 6-well
plate for 24 h. One hundred microlitres of 2 μM ITGA3 siRNA SMARTpool, WWOX
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siRNA SMARTpool (Dharmacon, Lafayette, CO, USA), oligo 1, 15 or non-targeting
oligonucleotide pool 2 (Perbio, Helsingborg, Skane Lan, Sweden) were mixed with
100 μl of Optimem media and incubated for 5 min. Three microlitres of Dharmafect
transfection reagent 1 (Perbio) was incubated with 197 μl Optimem media for 5 min,
combined with relevant siRNA solution for 20 min, mixed with medium and added to
cells. To measure the level of ITGA3 knockdown, cells were collected 72 h post
transfection, fixed with 2% paraformaldehyde and blocked with 1% BSA. Cells
(2 × 105) were stained with 1:100 dilution of ITGA3 antibody (Millipore), followed by
incubation with 1:500 dilution of secondary FITC-conjugated antibody (Sigma) and
analysed by FACS.
Quantitative RT-PCR. QRT-PCR was conducted as described previously.19
Primer sequences: TGFBI (5′-ATGGGGACTGTCATGGATGT-3′ and 5′-TGTAGA
CTCCTTCCCGGTTG-3′), PPIA (5′-CTGCACTGCCAAGACTGA-5′ and 5′-GCCAT
TCCTGGACCCAAA-3′), TUBA1B (5′-GCCAAGCGTGCCTTTGTTC-3′ and 5′-CA
CACCAACCTCCTCATAATCC-3′).
Protein arrays. Cells were plated and treated as for Annexin V assays. Cell
lysates from three experiments (100 μg protein each) were combined, incubated
with human apoptosis protein or phosphoprotein arrays (ARY009 and ARY003;
R&D Systems) and processed as per the manufacturer’s protocol. The films were
scanned with transmission-mode scanner and pixel densities analyzed with
ImageQuant (GE Healthcare, Chicago, IL, USA).
Western blotting. Western blotting was conducted according to standard
protocols. The antibodies used in this study were as follows: rabbit anti-WWOX
(a kind gift of Dr. M Aldaz, MD Anderson Cancer Centre, Houston, TX, USA) and
ab137726 antibody (abcam), rabbit anti-β-actin (no. 4970; Cell Signalling
Technology, Danvers, MA, USA), rabbit anti-Hsp60 (abcam; ab46798), rabbit anti-
cleaved (Asp175) caspase-3 (R&D Systems, Minneapolis, MN, USA; 269518),
mouse caspase-2 (no. 2224; Cell Signalling Technology), rabbit caspase-7 (no.
9492; Cell Signalling Technology), rabbit anti-phospho-eIF2A (Cell Signalling
Technology; 9721), mouse anti-GRP78 (474421; R&D Systems), mouse anti-JNK1/
JNK2 252323, MAB2076 and rabbit AF1205 (phospho-JNK) (R&D Systems), rabbit
anti-phospho (T183/Y185)-JNK (AF1205), rabbit IRE-1 (ab48187 and ab37073;
abcam) and PERK (no. 3192; Cell Signalling Technology).
Co-immunoprecipitation. The cells were cultured on 15-cm Petri dishes and
collected when they reached 70–80% confluence (when using PEO1 stable
transfectants the medium with blasticidin was replaced with media without the drug
24 h before plating for the experiment). The cells were washed with ice-cold PBS, and
detached with a cell scraper into 5 ml volume of fresh PBS, centrifuged and lysed
immediately or stored as a pellet in − 80 °C. Cells collected from each dish were
lysed in 400 μl of the following buffer for 30 min on ice (0.5–1% Triton X or 0.5–1%
NP40, 10% glycerol, 150 mM NaCl, 50 mM Tris-HCl (pH= 7.2), 0.2 mM Na3VO4,
50 mM NaF, 2 mM EDTA, 1 mM PMSF, supplemented with 100 U/ml aprotinin, 10 μg/
ml leupeptin and 1 μg/ml pepstatin). The lysates were centrifuged at 13 000 r.p.m. at
4 °C for 20 min and the supernatant was transferred to a new tube. The supernatant
in each tube was precleared by incubation for 1 h with 10 μl of Protein A/G UltraLink
Resin (Pierce, Waltham, MA, USA; no. 53132). Two micrograms of a relevant or
control antibody as appropriate was added to each precleared sample and incubated
at 4 °C on a circular shaker for 3–6 h. Subsequently, 10 μl of the resin was added to
each sample and incubated at 4 °C on a circular shaker for 3 h to overnight. The
beads pellets were washed four times with the lysis buffer and resuspended in 30 μl
of 1xPAGE loading buffer (Fermentas, Waltham, MA, USA; no. R0611), 76
supplemented with DTT to the final concentration of 100 mM and boiled at 95 °C for
5 min. The immunoprecipitates were analysed by immunoblotting as described above.
Bioinformatics and statistical analysis. The TCGA data set, featuring
over 500 primary tumour samples, was obtained from The Cancer Genome Atlas
(https://tcga-data.nci.nih.gov/tcga/). The ‘Tothill’ data set featuring nearly 300
primary tumour samples was obtained from Gene Expression Omnibus (series
accession GSE9891). Raw gene expression data (Affymetrix CEL files) were
obtained for each data set and normalised using RMA.32 Statistics derived from Cox
proportional hazards models were used to evaluate the quantitative association
between a unit increase of some measure of term(s) of interest and either PFS time
or OS time. Dichotomisation of patient cohorts into higher-than-median expression
of a gene of interest and lower-than-median expression of the gene of interest was
carried out for the purposes of illustrating effects in Kaplan–Meier plots. Statistical
significance of differences in survival curves were evaluated using log-rank tests.
Linear models were fitted with LIMMA to derive F-statistics to assess the variation of
a given probe’s measured gene expression levels across samples grouped
according to the categorical clinical variables ‘residual disease following primary
surgery’ and ‘molecular subtype’.
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